Health Outcomes of Using Antipsychotics
Antipsychotics are crucial medications for treating and managing psychiatric conditions. These medications, which include both first-generation and second-generation antipsychotics, have significantly transformed mental health care by reducing symptoms and enhancing patients' quality of life. However, antipsychotics are associated with a range of outcomes, encompassing both therapeutic benefits and potential adverse effects. The significance of this Research Topic lies in optimizing treatment strategies by examining long-term health implications, assessing drug efficacy, and exploring real-world evidence. A comprehensive understanding of the health outcomes associated with antipsychotic use is essential for developing effective treatment approaches.This Research Topic aims to achieve several key objectives:•Investigate the long-term health implications associated with the use of antipsychotics. •Assess the therapeutic efficacy of these medications across different psychiatric disorders and patient populations . •Explore individual variations in response to antipsychotics •Identify strategies to minimize adverse effects while maintaining therapeutic benefits.The scope of this Research Topic focuses on the health outcomes associated with antipsychotic use. We welcome submissions of original research, brief research reports, systematic reviews, and meta-analyses that address the following themes:Therapeutic Efficacy: Studies evaluating the effectiveness of first-generation and second-generation antipsychotics in the management of psychiatric disorders.Adverse Effects: Research on the short- and long-term adverse effects of antipsychotic use.Real-World Evidence: Contributions providing real-world data on antipsychotic use, adherence, and health outcomes in diverse settings. Topic editors: Yifei Liu, Nathaniel Rickles, Megan Ehret Source: https://www.frontiersin.org/research-topics/70854/health-outcomes-of-using-antipsychotics
Articles in this collection
No articles published in this topic yet.
